.jpg)
.png)
Last Updated: Thursday, 02-Jul-2020 18:00:00 EDT
Join us Virtually in September for National Cholesterol Education Month
As we’ve monitored the trajectory of COVID-19 cases and local restrictions in the conference’s host city of Washington DC, we have decided to cancel the live Fall Clinical Lipid Update and associated pre-conference courses, scheduled for September 11-13, 2020.
Introduction
Article By:
LUKE HAMILTON, MS
Department of Pediatric Endocrinology and Diabetes
Cook Children’s Medical Center
Fort Worth, TX
DON P. WILSON, MD, FNLA
Department of Pediatric Endocrinology and Diabetes
Cook Children’s Medical Center
Fort Worth, TX
Diplomate, American Board of Clinical Lipidology
CATHERINE J. McNEAL, MD, PhD, FNLA
Department of Internal Medicine
Division of Cardiology
Baylor Scott and White Health
Temple, TX
Diplomate, American Board of Clinical Lipidology
Imagine the following scenario:
Article By:
NICOLE CIFFONE, MSN, ANP-C, AACC, CLS, FNLA
Nurse Practitioner
Arizona Center for Advanced Lipidology
Tucson, AZ
SUSAN HALLI-DEMETER, DNP, FNP-BC, CLS, FNLA
Nurse Practitioner
Mayo Clinic
Scottsdale, AZ
HMG-CoA reductase inhibitors (statins) were FDA-approved in 1987 and their introduction has revolutionized lipid and cardiovascular (CV) management for the past three decades.(1,2,3,4) Despite this, statins may be the most maligned pharmaceutical agents ever introduced. There are multiple potential causes for statin non-adherence and discontinuation. (5) Real and perceived side effects are cited as a critical contributor to this phenomenon.
Article By:
ROBERT E. LENDING, MD
Arizona Community Physicians
Cypress Concierge Medicine
Tucson, AZ
Diplomate, American Board of Clinical Lipidology
High density lipoprotein (HDL) has long been known as a negative risk factor for the development of atherosclerosis and cardiovascular disease. The traditional explanation of HDL’s atheroprotective effect is termed reverse cholesterol transport. In this process, HDL removes cholesterol from the periphery and delivers it to the liver to be excreted into the bile. However there are many other proposed protective mechanisms of HDL in addition to reverse cholesterol transport.
Article By:
NEIL SHETH, MD, FNLA
Senior Research Physician
Synexus Clinical Research
Glendale, AZ
Diplomate, American Board of Clinical Lipidology
Hypertriglyceridemia has become a point of great interest lately in the search for better management of residual risk in patients with established ASCVD. The Reduction of Cardiovascular Events with Icosapent Ethyl Intervention Trial (REDUCE-IT) as authored by Bhatt, DL et al, shows strong evidence that icosapent ethyl, in addition to statin, significantly reduced ASCVD risk in patients with hypertriglyceridemia.
Article By:
EDUARDO CABALLERO, MD
Mercedes, TX
Diplomate, American Board of Clinical Lipidology
JOSEPH L. LILLO, DO, CPI, FAPCR, FNLA
President, Southwest Lipid Association (2019-2020)
Associate Professor, Family Medicine
Midwestern University
Glendale, AZ
Private Practice
Scottsdale, AZ
Diplomate, American Board of Clinical Lipidology
T.S. is a 58-year-old male of South Asian origin who sought attention for complex dyslipidemia. He had migrated to the US in 1988. He has a strong family history positive for multiple members having coronary artery disease (CAD), percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), diabetes (DM) and one sibling with sudden cardiac death from a myocardial infarction (MI). He has been healthy all his life with no history of hypertension (HTN), smoking or DM.
Article By:
KRISHNASWAMI VIJAYARAGHAVAN, MD, FACC, FNLA
Medical Director, CHF
Abrazo Health Network
Clinical Professor of Medicine
University of Arizona
Phoenix, AZ
Diplomate, American Board of Clinical Lipidology
DINESH KALRA, MD, FACC, FSCCT, FSCMR
Associate Professor of Medicine
Rush Medical College
Director, Advanced Cardiac Imaging
Director, Lipid Clinic and Infiltrative Cardiomyopathy Program
Division of Cardiology, Rush Health System
Chicago, IL
First off, I would like to wish you all well and offer you a warm e-embrace on behalf of the LipidSpin team. I would also like to apologize for the delay in releasing this issue featuring the SWLA; we’ve been a bit distracted by a global health crisis and our schedule got pushed back.
Article By:
DANIEL E. SOFFER MD, FACP, FNLA
Editor, LipidSpin
Clinical Associate Professor of Medicine
University of Pennsylvania
Internal Medicine and Preventive Cardiology
University of Pennsylvania Health System
Philadelphia, PA
Diplomate, American Board of Clinical Lipidology
It is my privilege to proudly present this edition of LipidSpin from the Southwest Chapter of the National Lipid Association (SWLA). This chapter includes the states of Arizona, Colorado, New Mexico, Texas, Louisiana, Oklahoma, and Wyoming. This edition will address some new topics not covered before, as well as reinforce current ideas considered mainstream by lipid specialists nationwide. I am also pleased to share a very important article by my good friend, Dr.
Article By:
JOSEPH L. LILLO, DO, CPI, FAPCR, FNLA
President, Southwest Lipid Association (2019-2020)
Associate Professor Family Medicine Midwestern University
Glendale, AZ
Private Practice
Scottsdale, AZ
Diplomate, American Board of Clinical Lipidology
Last Updated: Monday, 22-Jun-2020 14:00:00 EDT
The Winner is...Trevor Hadley, BS!
The National Lipid Association (NLA) and the Foundation of the NLA are proud to announce the winner of the 2020 Young Investigator Award for outstanding lipid research: Trevor D. Hadley, BS, Baylor College of Medicine, Houston, Texas, for abstract 213 titled:
Genetic Testing for Hypertriglyceridemia--Experience from a single center lipid clinic
Congratulations to Aleesha Shaik, MD, New York, NY, for winning second-place